WHO ICTRP trial
A Randomized Phase 2 Trial to Evaluate Three Daratumumab Dose Schedules in…
NL-OMON54517 · Overview of Medical Research in the Netherlands (NL-OMON) · Recruiting
Key facts
| Trial ID | NL-OMON54517 |
|---|---|
| Public title | A Randomized Phase 2 Trial to Evaluate Three Daratumumab Dose Schedules in Smoldering Multiple Myeloma |
| Scientific title | A Randomized Phase 2 Trial to Evaluate Three Daratumumab Dose Schedules in Smoldering Multiple Myeloma - 54767414SMM2001 / Centaurus |
| Primary sponsor | Janssen-Cilag |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | 2 |
| Countries | The Netherlands |
| Conditions | Smoldering Multiple Myeloma - asymptomatic plasma cell disorder;10018865;Smoldering Multiple Myeloma - asymptomatic plasma cell disorder |
| Interventions | Refer to table 3 on page 18 of the protocol. ;Daratumumab;Multiple Myeloma;Smoldering |
| Registration date | Mar 27, 2023 |
| Target size | 6 |
| Secondary IDs | 2014-005139-14;NCT02316106;NL52170.029.15 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: